DOI:
10.1055/s-00000097
Deutsche Zeitschrift für Onkologie
LinksClose Window
References
Yang Q, Modi P, Newcomb T et al.
Idelalisib: First-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma.
Clin Cancer Res 2015;
21(7): 1537-1542
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.